

# SA Xinyi Glass



# Timothy Lee, CFA

timothy.lee@clsa.com +852 2600 8461

Tim Cheung +852 2600 8588

8 November 2016

# China Materials

Reuters 0868 HK Bloomberg 868 HK

Priced on 8 November 2016 HS CEI @ 9,659.9

12M hi/lo HK\$7.53/3.48

12M price target	HK\$8.30
±% potential	+37%
Shares in issue	3,891.4m
Free float (est.)	43.9%
Market cap	US\$3,171m
<b>3M average daily</b>	<b>volume</b>
HK\$91.3m	(US\$11.8m)

Foreign s'holding 52.7%

**Major shareholders** Lee Yin Yee 21.7% Tung Ching Sai 9.7%

# Stock performance (%)



www.clsa.com

# **Concerns priced in**

# Higher auto glass export rebate is a positive

XYG's share price corrected c.20% in the past 2 months, mainly on concerns about property sector outlook and capacity growth. Meanwhile, we expect a relatively balanced float glass demand/supply in 17CL, given property restrictions are more focused in specific regions, and further restart/ brand new capacity are limited from here. Natural gas price hike is also likely seasonal. Besides, auto glass export tax rebate would help margin. We retain BUY on XYG despite property restrictions and slack season could drag sentiment, but we see potential positive profit alert in Dec and natural gas price cut amid transmission tariff reform as catalysts. We have also adjusted our TP from HK\$8.35 to HK\$8.30.

# Float glass: Slack season comes, balanced demand/supply in 17CL

Float glass starts to enter slack season, so industry data will not be impressive short term. Meanwhile, property restrictions would affect sales and new starts growth outlook in 2017 but measures are still mainly in regions with more property price hikes and yet to be nationwide, thus glass demand would not likely decline massively. For supply, we noted restart of overhaul production lines YTD amid improved glass profitability, but we see additional restarts and brand new production lines to be limited from here as well. We expect relatively balanced demand-supply dynamics for float glass in 17CL.

# Cost: Natural gas price hike is seasonal

We see the recent 10-20% natural gas price hike attempt by PetroChina as seasonal to balance stronger gas demand during winter, which will only add to float glass cost by c.0.3%/0.6% in 16/17CL, or c.0.6%/1.5% cut in profit. On the flip side, transmission tariff reform will likely lower gas prices and in turn benefit large-scale gas users with direct purchases from suppliers like XYG.

# Auto glass: Increased export rebate

The MoF also recently lifted export tax rebate from 13% to 17% for >400 products, including auto glass, effective since 1 Nov (link). Approx. 75% of XYG's auto glass is for export, thus this would result in reduction in costs and higher margin – we estimate a c.3% positive impact to 17CL profit.

# Negatives mostly priced in; retain BUY

We fine-tuned our 16/17/18CL core profit forecasts by -1.3%/-1.1%/0% due to higher auto glass export rebate, offset by seasonal natural gas price hike and our recent cut on solar glass price for XYS. We have also adjusted our TP from HK\$8.35 to HK\$8.30, which is based on a blended PE and PB approach.

Financials										
Year to 31 December	14A	15A	16CL	17CL	18CL					
Revenue (HK\$m)	10,861	11,460	13,112	13,719	14,217					
Rev forecast change (%)	-	-	0.0	3.3	3.0					
Adjusted net profit (HK\$m)	1,144	1,734	2,992	3,583	3,969					
NP forecast change (%)	-	-	(1.3)	(1.1)	0.0					
Adjusted EPS (HK¢)	28.4	43.0	74.5	89.6	99.2					
CL/consensus (8) (EPS%)	-	-	96	98	101					
Adj EPS growth (% YoY)	(45.3)	51.7	73.2	20.2	10.8					
Adjusted PE (x)	21.3	14.1	8.1	6.8	6.1					
Dividend yield (%)	2.5	4.4	6.2	7.5	8.3					
ROE (%)	11.1	16.9	22.4	24.1	23.6					
Net debt/equity (%)	42.0	37.2	36.9	24.9	12.6					
Source: CLSA										

Find CLSA research on Bloomberg, Thomson Reuters, Factset and CapitaIIQ - and profit from our evalu@tor proprietary database at clsa.com

# For important disclosures please refer to page 11.



National average float glass pricing picked up YTD, and started to decline amid seasonal weakness



Source: WIND, CLSA





Figure 3

#### Float glass demand/supply dynamics (weight case, m) — Util Production Capacity 82% 1,200 80% 1,000 78% 76% 800 74% 600 72% 70% 400 68% 66% 200 64% 0 62% 2011 2012 2013 2014 2015 2016 2017 2018 Source: CLSA

We expect fairly stable demand/supply dynamics in 2017

Ltd.

#### Figure 4

YTD Property sales/new starts started to slow but not yet massively



Figure 6

Figure 7

Figure 5

Glass demand lags behind property sales



Some production lines resumed operation from overhaul amid improved profitability YTD, but we expect <10 lines will resume further from here



Float glass inventory level started to increase amid seasonal factor





Source: CLSA

Source: NBS, CLSA





Higher export tax rebate

for auto glass

List of products enjoying higher export tax rebate

# 提高出口退税率的产品清单

序号	产品编码	产品名称	调整后援 税率(%)
1	27101210	车用汽油及航空汽油	17
2	27101911	航空煤油	17
3	27101923	柴油	17
4	39093010	聚合MDI	17
5	68141000	粘聚或复制云母制的板、片、带	17
6	70022010	光导纤维预制棒	17
7	7006000001	液晶玻璃基板,6代以上,不含6代	17
8	7006000002	液晶玻璃基板,6代及以下	17
9	70071190	车辆用钢化安全玻璃	17
10	70072190	车辆用层压安全玻璃	17
11	70199021002	多层印制电路板用玻璃纤维布浸胶制粘结片	17
12	73158100	日字环节链	17

Source: MoF, CLSA

increase in transportation costs; and 2) suspension of operation temporarily by some supplier for maintenance

8 November 2016

#### Figure 10

#### **Earnings revisions**

		16CL				
_	New	Old	Change	New	Old	Change
Revenue (HK\$ m)	13,112	13,112	0.0%	13,719	13,282	3.3%
- Automobile glass products	3,978	3,978	0.0%	4,102	4,052	1.2%
- Construction glass	2,635	2,635	0.0%	2,529	2,424	4.3%
- Float glass (inc. electronic glass)	6,463	6,463	0.0%	6,883	6,602	4.3%
- Wind farm	37	37	0.0%	204	204	0.0%
Gross profit margin	35.1%	35.1%	0.0 ppt	37.2%	37.5%	-0.3 ppt
- Automobile glass products	49.2%	48.7%	0.4 ppt	52.5%	51.2%	1.3 ppt
- Construction glass	39.0%	39.1%	-0.1 ppt	38.7%	39.1%	-0.5 ppt
- Float glass (inc. electronic glass)	24.7%	24.9%	-0.3 ppt	26.7%	27.5%	-0.8 ppt
- Wind farm	70.3%	70.3%	0.0 ppt	70.3%	70.3%	0.0 ppt
Core profit (HK\$ m)	2,992	3,030	-1.3%	3,583	3,622	-1.1%

# Our TP is based on a blended PE and PB approach

Current market-cap
implies 7.3x/6.0x its non-
solar businesses earnings
in 16/17CL

Figure 11 Valuation of Xinyi Glass	
PE basis	
Average 17-18CL EPS (HK\$)	0.95
Target multiple (x)	10.0
Fair value (HK\$)	9.50
PB basis	
Average 16-17CL BVPS (HK\$)	3.71
Target multiple (x)	1.9
Fair value (HK\$)	7.10
Average (HK\$)	8.30
Implying 16/17CL PE	11.0x / 9.2x
Source: CLSA	
Figure 12	

	1633		
HK\$m		FY16CL	FY17CL
Net profit of Xinyi Glass		2,992	3,583
Less: after-tax share of profits of Xinyi Solar		(498)	(556)
Non-solar profit	(a)	2,494	3,027
Current market cap of Xinyi Glass	(b)	23,543	23,543
Current market cap of Xinyi Solar	(c)	18,897	18,897
M'cap of Xinyi Glass's non-solar business	(d) = (b) - 29.5%*(c)	18,082	18,082
PE of Xinyi Glass's non-solar business	(e) = (d) / (a)	7.3	6.0
Source: CLSA			

Source: CLSA







Source: CLSA, Datastream

8 November 2016

Figure 16

/aluation comp – Xinyi Glass																			
Stock	Ticker	Price	Mkt Cap	ADTV	_	CLSA			12m for				EPS Cagr	PEG	Gearing			ance (	· · ·
Xinyi Glass	868 HK	(local)	(USD,m) 3,036		Rec BUY	Target 8.30	-	PE	PB 1.5		EV/Ebitda 5.9	<b>ROE</b> 23.8	<b>FY1-FY3</b> 15.4	0.5	<b>(%)</b>	<b>1m</b> (16)	3m		12m
		6.05		11.8	BUY	8.30	37%	7.0		7.3					37	• •	(9)	29	68
Fuyao Glass - H	3606 HK	22.90	6,728	7.0				14.9	2.6	4.4	8.3	18.3	11.2	1.3	(7)	(1)	8	31	32
China Glass	3300 HK	0.89	208	0.2											47	(14)	(20)	(11)	(21)
Luoyang Glass	1108 HK	5.27	358	2.2											221	(17)	16	13	(6)
Fuyao Glass - A	600660 CH	17.72	6,728	26.2				13.5	2.3	4.9	8.3	18.2	11.8	1.1	(7)	5	7	25	26
Yaohua Pilkington	600819 CH	7.97	1,011	8.1											46	8	7	21	4
Shandong Jinjing	600586 CH	4.69	1,009	17.4				20.1	1.5		9.2	7.3	24.5	0.8	57	2	8	5	(19)
AVIC Sanxin	002163 CH	8.47	1,004	24.4					9.7			2.6			265	6	20	20	(16)
Xiuqiang Glasswork	300160 CH	12.05	1,062	15.4				51.7	4.8	0.6	30.8	10.9	27.3	1.9	1	1	5	(17)	57
Changzhou Almaden	002623 CH	55.35	1,306	30.6											(7)	46	69	76	57
Zhuzhou Kibing	601636 CH	3.92	1,508	37.2				14.3	1.6		6.8	11.3	9.7	1.5	82	6	19	16	(19)
Taiwan Glass	1802 TT	13.90	1,285	1.5											67	(6)	5	1	(1)
Asahi Glass	5201 JP	711.00	8,072	27.5	O-PF	780.00	10%	17.1	0.8	2.5	3.5	4.7	11.5	1.5	31	7	13	16	(1)
Nippon Sheet Glass	5202 JP	786.00	679	6.7				11.9	0.9	0.2	6.4	7.7	33.1	0.4	333	(5)	(3)	(4)	(27)
Central Glass	4044 JP	405.00	833	2.7				8.9	0.5	2.7	4.9	5.7	(0.0)		23	0	(3)	(31)	(32)
Hankuk Glass Industries	002000 KS	27,000.00	240	0.0											(16)	(1)	(4)	(1)	6
Cie de St-Gobain	SGO FP	39.60	24,298	58.3				14.5	1.1	3.2	6.9	7.8	14.3	1.0	25	4	3	3	(2)
PPG Industries Inc	PPG US	94.35	24,908	167.3	O-PF	115.00	22%	14.1	4.9	1.7	9.6	34.5	12.2	1.2	59	1	(10)	(13)	(8)
Turkiye Sise	SISE TI	3.18	2,051	5.4				8.7	0.8	4.0	5.9	8.5	14.8	0.6	15	(3)	(8)	(3)	3
Trakya Cam Sanayii	TRKCM TI	2.49	729	2.9				8.4	0.7	6.4	6.4	7.4	(20.0)		14	(2)	(3)	29	27
Corning	GLW US	22.98	21,859	215.0	SELL	20.00	(13%)	14.6	1.7	2.7	8.3	10.7	(1.3)		(0)	(3)	1	25	21
Average								15.7	2.4	3.4	8.6	12.0	11.8	1.1	61.2				

Source: Bloomberg, CLSA

# Valuation details

We value XYG using a blended PE and PB approach. We apply a target multiple of 10x to average 17-18CL EPS and a target multiple of 1.9x to average 16-17CL BVPS, in line with the historical averages.

### **Investment risks**

Key risks include: 1) Weakening of the property market or even the auto market. Demand for float glass and construction glass is highly dependent on the property market. Besides, despite being a stable business, the auto glass segment is correlated to the global number of vehicles in use, and any significant slowdown in the global auto industry may also affect the segment's performance. 2) Further tightening of credit. Tightening of credit also affects developers' cash flows and progress in construction of property projects. 3) Incremental production costs. A significant surge in natural gas, international crude oil prices and other raw material costs may affect XYG's gross margin if it cannot pass on incremental costs by raising ASP. 4) More capacity additions in the market.

# Valuation details - Asahi Glass Co Ltd 5201 JP

We value the stock using a PB valuation derived from a PB - ROE correlation. We use quarterly PB and ROE since 2010 for our linear regression. While we forecast Asahi Glass to see revenue and operating profit growth in the medium term as the US and Eurozone economies improve and chemicals experience success with new products along with growth in Southeast Asia, nonoperating costs are a slight drag on net profits and ROE. Our target price of ¥780 is based on a PB of 0.81x FY12/17CL estimates.

# Investment risks - Asahi Glass Co Ltd 5201 JP

Fluctuating fuel costs are a risk because almost all of its businesses consume large amounts of fuel and materials. A US\$1 fall in oil prices adds ¥400mn to OP. An increase in oil prices would cause a decline in profits profits. We expect the LCD substrate market to continue to see price cuts, but if weakness in downstream markets put more pressure on prices they may decline more than our expectations. The company is expecting ¥30bn in non-operating costs, but we are assuming ¥20bn. If non-operating costs reach ¥30bn, net profits would drop which would affect our PB-ROE correlation derived PB multiple.

# Valuation details - Corning Inc GLW US

Our price target of \$20 equates to a PE multiple of 12.6x applied to our 2017 EPS estimate of \$1.59. This reflects a 25% discount overall to the market multiple (in line with last few years) due to the low quality of its earnings, weak TV, partially offset by near term better panel demand trends, and includes part of its net cash and dividend and relatively stable pricing environment. Corning has a strong net cash position, pays dividends (about 3% yield), and we expect it to generate healthy free cashflow in 2016 that should limit further downside risk. At our price target, the stock would be discounting a 6% FCF yield on 17CL estimates.

# **Investment risks - Corning Inc GLW US**

Risks to our rating and price target include stabilizing weeks of inventory in the supply chain, a more favorable pricing environment, and improving profitability for Samsung Corning Precision and Dow Corning. Downside risks include an inability to diversify the business in the coming years, an extended inventory correction in LCD panels and Gorilla Glass in the coming quarters, and continued LCD glass price pressures not factored into our model.

# Valuation details - PPG Industries Inc PPG US

Our target price is based on a three-stage DCF model with explicit, mid-cycle and long-term phases. Each phase assumes asset growth, return on capital, capital structure and cost of debt representative of economic cycle and probable funding costs. In general, we assume return and asset growth fade to long-term trends, with return on invested capital generally approximating the firm's weighted average cost of capital over the long term. For cost of equity, we use a beta of one which approximates the firm's historical average, and a market risk premium of 6%.

# Investment risks - PPG Industries Inc PPG US

PPG's broad economic exposure suggests that in a weakening environment, the company's results are likely to suffer. The inability to effect meaningful M&A could harm PPG's long-term growth potential. Conversely, a large acquisition could harm the company's balance sheet by increasing debt levels to risky levels and substantially expanding interest costs and leverage. A downturn in global auto production would harm PPG's profitability given the end market represents close to 25% of the company's revenue in terms of OEM and refinish.





# **Summary financials**

	Summary	anciais				
	Year to 31 December	2014A	2015A	2016CL	2017CL	2018CL
	Summary P&L forecast (HK	(\$m)				
	Revenue	10,861	11,460	13,112	13,719	14,217
	Op Ebitda	1,740	2,313	3,638	4,238	4,578
	Op Ebit	1,095	1,518	2,761	3,279	3,546
Improving margins and	Interest income	53	40	52	48	42
higher associates profit to	Interest expense	(91)	(90)	(122)	(93)	(61)
drive earnings growth	Other items	536	912	798	906	1,046
	Profit before tax	1,593	2,380	3,490	4,140	4,573
	Taxation	(228)	(266)	(498)	(556)	(604)
	Minorities/Pref divs	(1)	0	0	0	0
	Net profit	1,364	2,113	2,992	3,583	3,969
	-		_,	_,	0,000	-,
	Summary cashflow forecast					
	Operating profit	1,095	1,518	2,761	3,279	3,546
	Operating adjustments	-	-	-	-	-
	Depreciation/amortisation	644	795	876	959	1,032
	Working capital changes	(559)	(207)	(246)	(59)	(62)
	Net interest/taxes/other	(314)	(421)	(620)	(649)	(665)
Concurrentially on wind	Net operating cashflow	867	1,685	2,772	3,531	3,851
Capex mainly on wind	Capital expenditure	(1,729)	(1,967)	(1,700)	(1,500)	(1,300)
farm and Malaysia	Free cashflow	(862)	(282)	1,072	2,031	2,551
investments	Acq/inv/disposals	93	-	(618)	-	-
	Int, invt & associate div	588	951	850	954	1,088
	Net investing cashflow	(1,049)	(1,016)	(1,468)	(546)	(212)
	Increase in loans	873	16	619	(1,611)	(1,647)
	Dividends	(902)	(1,029)	(1,471)	(1,762)	(1,952)
	Net equity raised/other	0	812	(265)	0	0
	Net financing cashflow	(30)	(202)	(1,117)	(3,374)	(3,599)
	Incr/(decr) in net cash	(211)	468	187	(390)	40
	Exch rate movements	1	-	-	-	-
	Opening cash	1,043	832	1,300	1,487	1,098
	Closing cash	832	1,300	1,487	1,098	1,137
	_					
	Summary balance sheet for	ecast (HK\$m)				
Balance sheet still healthy	Summary balance sheet for Cash & equivalents	ecast (HK\$m) 832	1,300	1,487	1,098	1,137
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors	ecast (HK\$m) 832 1,028	1,300 <mark>1,136</mark>	1,238	1,295	1,342
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories	ecast (HK\$m) 832 1,028 1,478	1,300 <mark>1,136</mark> 1,223	1,238 1,368	1,295 1,371	1,342 1,404
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets	ecast (HK\$m) 832 1,028 1,478 1,467	1,300 1,136 1,223 1,337	1,238 1,368 1,337	1,295 1,371 1,337	1,342 1,404 1,337
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets	ecast (HK\$m) 832 1,028 1,478 1,467 11,293	1,300 1,136 1,223 1,337 11,971	1,238 1,368 1,337 12,825	1,295 1,371 1,337 13,396	1,342 1,404 1,337 13,694
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366	1,300 1,136 1,223 1,337 11,971 1,281	1,238 1,368 1,337 12,825 1,250	1,295 1,371 1,337 13,396 1,220	1,342 1,404 1,337 13,694 1,191
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570	1,300 1,136 1,223 1,337 11,971 1,281 3,174	1,238 1,368 1,337 12,825 1,250 3,792	1,295 1,371 1,337 13,396 1,220 3,792	1,342 1,404 1,337 13,694 1,191 3,792
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b>	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b>	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b>	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b>
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7	1,295 1,371 1,337 12,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974	1,295 1,371 1,337 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7	1,295 1,371 1,337 12,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974	1,295 1,371 1,337 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b>	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b>	1,295 1,371 1,337 1,200 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b>	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b>
Balance sheet still healthy	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b>	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b>	1,295 1,371 1,337 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b>	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b>
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2,233 21,034 9,3 (37.7)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b>	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3	1,295 1,371 1,337 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16,5	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2,2333 21,034 9,3 (37.7) 16.0	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7	1,295 1,371 1,337 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2,2333 21,034 9,3 (37.7) 16.0 12.6	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2,233 21,034 9,3 (37.7) 16.0 12.6 44.4	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Other current assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%)	ecast (HK\$m) 832 1,028 1,478 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37.7) 16.0 12.6 44.4 14.3	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37.7) 16.0 12.6 44.4 14.3 45.7	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3 52,2	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4 95.2	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2 236.9
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Ebitda/net int exp (x) Net debt/equity (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37.7) 16.0 12.6 44.4 14.3 45.7 42.0	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3 52,2 36,9	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4 95.2 24.9	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2 236.9 12.6
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37,7) 16.0 12.6 44.4 14.3 45.7 42.0 11.1	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3 52,2 36,9 22,4	1,295 1,371 1,337 1,3396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4 95.2 24.9	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2 236.9 12.6 23.6
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37.7) 16.0 12.6 44.4 14.3 45.7 42.0 11.1 6,2	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9 8.7	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3 52,2 36,9 22,4 15,1	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4 95.2 24.9 24.1 17.2	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2 236.9 12.6 23.6 18.1
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%) ROIC (%) EVA®/IC (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37,7) 16.0 12.6 44.4 14.3 45.7 42.0 11.1	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3 52,2 36,9 22,4	1,295 1,371 1,337 1,3396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4 95.2 24.9	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2 236.9 12.6 23.6
	Summary balance sheet for Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%)	ecast (HK\$m) 832 1,028 1,478 1,467 11,293 1,366 3,570 21,034 2,529 724 1,548 3,483 414 2 12,333 21,034 9,3 (37.7) 16.0 12.6 44.4 14.3 45.7 42.0 11.1 6,2	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9 8.7	1,238 1,368 1,337 12,825 1,250 3,792 <b>23,298</b> 2,772 741 1,705 3,875 223 7 13,974 <b>23,298</b> 14,4 57,3 27,7 22,8 50,7 14,3 52,2 36,9 22,4 15,1	1,295 1,371 1,337 13,396 1,220 3,792 <b>23,509</b> 2,100 743 1,705 2,936 223 7 15,795 <b>23,509</b> 4.6 16.5 30.9 26.1 50.6 13.4 95.2 24.9 24.1 17.2	1,342 1,404 1,337 13,694 1,191 3,792 <b>23,898</b> 1,414 761 1,705 1,976 223 7 17,812 <b>23,898</b> 3.6 8.0 32.2 27.9 50.6 13.2 236.9 12.6 23.6 18.1





## **Research subscriptions**

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

# **Companies mentioned**

Xinyi Glass (868 HK - HK\$6.05 - BUY)1 Asahi Glass (5201 JP - ¥711 - OUTPERFORM)<sup>1</sup> AVIC Sanxin (N-R) Central Glass (N-R) Changzhou Almaden (N-R) China Glass (N-R) Corning (GLW US - US\$22.98 - SELL)<sup>2</sup> Fuyao Glass - H (N-R) Fuyao Glass (N-R) Hankuk Glass Ind (N-R) Jinjing (N-R) Kibing (N-R) Luoyang Glass (N-R) NSG (N-R) PetroChina (857 HK - HK\$5.40 - BUY)1 PPG (PPG US - US\$94.35 - OUTPERFORM)<sup>2</sup> Saint-Gobain (N-R) Sise Cam (N-R) SYP Glass (N-R) Taiwan Glass (N-R) Trakya Cam Sanayii (N-R) Xinyi Solar (968 HK - HK\$2.80 - BUY)1 Xiuqiang Glasswork (N-R)

<sup>1</sup> Covered by CLSA; <sup>2</sup> Covered by CLSA Americas

# Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.







Source: CLSA

The policy of CLSA (which for the purpose of this disclosure includes subsidiaries of CLSA B.V. and CLSA Americas, LLC ("CLSA Americas")), and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts may not receive compensation from the companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of discloseable position should not be taken а as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of CLSA's research, our Corporate Finance, Sales Trading and Research business lines are distinct from one another. This means that CLSA's Research department is not part

of and does not report to CLSA Corporate Finance (or "investment banking") department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management.

CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading and Research activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Neither	analysts	nor	their	household
---------	----------	-----	-------	-----------



members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a preexisting holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLSA Americas/CLST did not receive investment banking/noninvestment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLSA Americas/CLST does not own a material discloseable position, and does not make a market, in the securities.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLSA Americas/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12month forecast return (including dividends) for the market on which the stock trades.

In the case of US stocks, the recommendation is relative to the expected return for the S&P500 of 10%. Exceptions may be made depending upon prevailing market conditions. We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLSA Americas only /CLST only Universe:

Overall rating distribution: Buy / Outperform - CLSA: 60.57%; CLSA Americas only: 58.89%; CLST only: 70.42%, Underperform / Sell - CLSA: 39.28%; CLSA Americas only: 41.11%; CLST only: 29.58%, Restricted - CLSA: 0.00%; CLSA Americas only: 0.00%; CLST only: 0.00%. Data as of 30 September 2016.

Investment banking clients as a % of rating category: Buy / Outperform - CLSA: 2.78%; CLSA Americas only: 0.00%; CLST only: 0.00%, Underperform / Sell - CLSA: 2.79%; CLSA Americas only: 0.00%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLSA Americas only: 0.00%; CLST only: 0.00% . Data for 12-month period ending 30 September 2016.

There are no numbers for Hold/Neutral as CLSA/CLSA Americas/CLST do not have such investment rankings.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: (a) CLSA Americas, Compliance Department, 1301 Avenue of the Americas, 15th Floor, New York, New York 10019-6022; (b) CLSA, Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (c) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). © 2016 CLSA Limited, CLSA Americas, and/or CLST.

© 2016 CLSA Limited, CLSA Americas, LLC ("CLSA Americas") and/or CL Securities Taiwan Co., Ltd. ("CLST")

This publication/communication is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (www.clsa.com/disclaimer.html.). Neither the publication/communication nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA group of companies (excluding CLSA Americas, LLC) ("CLSA"), CLSA Americas (a broker-dealer registered with the US Securities and Exchange Commission and an affiliate of CLSA) and/or CLST.

CLSA, CLSA Americas and CLST has/have produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only. This publication/communication may not be distributed or redistributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA, CLSA Americas and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA, CLSA Americas and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA, CLSA Americas and/or CLST. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. CLSA, CLSA Americas and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA, CLSA Americas and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, CLSA, CLSA Americas, CLST, their respective

affiliates or companies or individuals connected with CLSA/CLSA Americas/CLST may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that CLSA, CLSA Americas, CLST and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research\_disclosures/. Disclosures therein include the position of CLSA, CLSA Americas and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company covered in this publication/communication.. If investors have any difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited (formerly CLSA India Limited), (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in United Kingdom by CLSA (UK).

disclosure information on previous dates, please contact

compliance hk@clsa.com.

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

Canada: The delivery of this research report to any person in Canada shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in Canada wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive

research material.

Singapore: In Singapore, research is issues and/or distributed by CLSA Singapore Pte Ltd (Company Registration No.: 198703750W), a Capital Markets Services license holder to deal in securities and an exempt financial adviser, a solely to persons who qualify as an institutional investor, accredited investor or expert investor, as defined in s.4A(1) of the Securities and Futures Act. Pursuant to Paragraphs 33, 34, 35 and 36 of the Financial Advisers (Amendment) Regulations 2005 of the Financial Advisers Act (Cap 110) with regards to an institutional investor, accredited investor expert investor or Overseas Investor, sections 25, 27 and 36 of the Financial Adviser Act (Cap 110) shall not apply to CLSA Singapore Pte Ltd. Please contact CLSA Singapore Pte Ltd (telephone No.: +65 6416 7888) in connection with queries on the report. MCI (P) 033/11/2016

The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity (including CLSA Americas), CLST or a subsidiary of CITIC Securities Company Limited which is different from the entity that distributes the publication/communication in the respective jurisdictions.

MSCI-sourced information is the exclusive property of Morgan Stanley Capital International Inc (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly all warranties of originality, disclaim accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are service marks of MSCI and its affiliates. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by CLSA.

EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA/CLSA Americas and "CT" stands for CLST estimates unless otherwise noted in the source.